AIM ImmunoTech Inc. AIM
Nov 6, 2026, 10:31 AM EST
- YTD
- -85.56%
- 1 year
- -90.20%
- Market cap
- 6.34M
- Revenue (ttm)
- 201.00K
- EPS (ttm)
- -2.98
- Shares out
- 63.78M
- Forward P/E
- -0.48
- YTD return
- -85.56%
- 1-year return
- -90.20%
- Volume
- 222.42K
- Avg volume
- 4.47M
- Open
- 0.152
- Previous close
- 0.1521
- Day's range
- 0.1476 – 0.1588
- 52-week range
- 0.1476 – 1.82
- Beta
- -0.36
- Analysts
- Strong Buy
- Price target
- 2.75 (+1631.7%)
5D -0.0012 (-0.75%)
Key statistics
- Enterprise value
- 6.04M
- PEG ratio
- 0.00
- Price / sales
- 61.88
- Price / book
- 1.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 19.00%
- Free cash flow
- -16.04M
- Total cash
- 10.06M
- Total debt
- 3.36M
- Return on equity
- -154.79%
- Short % of float
- 0.85%
- 50-day average
- 0.232
- 200-day average
- 0.338
Analyst view
Consensus: strong buy
- Target (low)
- 1.00
- Target (mean)
- 2.75
- Target (high)
- 4.50
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.10 | -0.06 | +0.04 | +40.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| May 16, 2024 | Mar 1, 2024 | 0.00 | -0.12 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.26 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.16 | — | — |
| Aug 15, 2023 | Jun 1, 2023 | 0.00 | -0.10 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Oct 22, 2024 | Maxim Group | main | Buy | Buy |
| Sep 3, 2024 | Ascendiant Capital | main | Buy | Buy |
| Oct 10, 2019 | Maxim Group | up | Hold | Buy |
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aimimmuno.com
News
AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer 
12 Health Care Stocks Moving In Monday's Intraday Session 
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7 - AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY
AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study 
AIM ImmunoTech Outlines Upcoming Milestones, Including DURIPANC Primary Endpoint Analysis Expected In December 2026 - 12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session - AIM ImmunoTech Commences ~$2.65M Registered Direct Offering Of 2.554M Common Shares At $0.5189/Share
- AIM ImmunoTech Files Prospectus For Resale Of Up To 31,287,933 Shares
Your note
Sign in to keep a note on AIM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPELROUTH STEWART L. | Director | Stock Award(Grant) | Dec 12, 2024 | 379,961 |
| BRYAN NANCY K | Director | Stock Award(Grant) | Dec 12, 2024 | 85,559 |
| EQUELS THOMAS K | Chief Executive Officer | Purchase | Dec 17, 2024 | 1,680,700 |
| MITCHELL WILLIAM M | Director | Sale | Dec 18, 2024 | 118,929 |
| RODINO PETER W III | Chief Operating Officer | Stock Award(Grant) | Aug 11, 2024 | 401,262 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 6.79% | 4,330,000 | 844.35K | Sep 29, 2024 |
| Vanguard Group Inc | 3.12% | 1,988,704 | 387.80K | Sep 29, 2024 |
| Blackrock Inc. | 1.09% | 698,267 | 136.16K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.73% | 464,016 | 90.48K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.72% | 457,767 | 89.26K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.38% | 243,208 | 47.42K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.06% | 1,311,599 | 255.76K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.97% | 620,229 | 120.94K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 303,016 | 59.09K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 71,505 | 13.94K | Oct 30, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.07% | 43,668 | 8.52K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 36,509 | 7.12K | Oct 30, 2024 |